Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half-Year ended September 30, 2026 (Q2 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to SEBI Listing Regulations

Audit Opinion:

The Statutory Auditors, Deloitte Haskins & Sells LLP, issued an unmodified conclusion on the limited review of both standalone and consolidated financial results.

Auditor’s Comment:

Not Specified

Key Financial Highlights [₹ Crores]:

Consolidated Results:

Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from Operations: ₹2,206.37 (vs. ₹1,653.47 in Q2 FY26; +33.4% YoY)
  • Total Income: ₹2,219.38
  • EBITDA: Not explicitly disclosed
  • Net Profit: ₹436.74 (vs. ₹193.75 in Q2 FY26; +125.4% YoY)
  • EPS: ₹8.17 (Basic) / ₹8.16 (Diluted)
  • Other Equity: ₹5,952.51 (as of September 30, 2026)
  • Cash and Cash Equivalents: ₹24.45
  • Debt: Total Borrowings (Current + Non-current) = ₹1,936.56 (Current) + ₹553.32 (Non-current) = ₹2,489.88

Half-Year Ended September 30, 2026 (H1 FY27):

  • Revenue from Operations: ₹4,232.68 (vs. ₹3,223.04 in H1 FY26; +31.3% YoY)
  • Total Income: ₹4,254.87
  • Net Profit: ₹798.73 (vs. ₹354.83 in H1 FY26; +125.1% YoY)
  • EPS: ₹14.98 (Basic) / ₹14.96 (Diluted)

Standalone Results:

Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from Operations: ₹2,014.11 (vs. ₹1,566.60 in Q2 FY26; +28.6% YoY)
  • Total Income: ₹2,038.83
  • Net Profit: ₹388.13 (vs. ₹215.67 in Q2 FY26; +80.0% YoY)
  • EPS: ₹7.18 (Basic and Diluted)
  • Other Equity: ₹5,774.33 (as of September 30, 2026)
  • Cash and Cash Equivalents: ₹0.24
  • Debt: Total Borrowings (Current + Non-current) = ₹1,737.06 (Current) + ₹348.92 (Non-current) = ₹2,085.98

Half-Year Ended September 30, 2026 (H1 FY27):

  • Revenue from Operations: ₹3,771.27 (vs. ₹2,999.35 in H1 FY26; +25.7% YoY)
  • Total Income: ₹3,816.06
  • Net Profit: ₹678.09 (vs. ₹373.61 in H1 FY26; +81.5% YoY)
  • EPS: ₹12.55 (Basic) / ₹12.54 (Diluted)

Segment-wise Performance:

The Group is engaged in a single reportable business segment: 'Pharmaceuticals' as per Ind AS 108.

Corporate Actions:

Dividend:

  • The Board approved an Interim Dividend of ₹1.00 per equity share (50% on face value of ₹2 each) for FY 2026-27.
  • Record Date: November 6, 2026.
  • Payment Date: On or after November 19, 2026.

ESOP Allotment:

  • During H1 FY27, the company allotted 455,636 equity shares of ₹2 each consequent to the exercise of stock options by employees.

Other Significant Information:

Entities in Consolidation:

The consolidated results include the following entities:

  • Laurus Labs Limited (Parent)
  • Laurus Bio Private Limited, India (Subsidiary)
  • Sriam Labs Private Limited, India (Wholly Owned Subsidiary)
  • Laurus Synthesis Private Limited, India (Wholly Owned Subsidiary)
  • Laurus Holdings Limited, UK (Wholly Owned Subsidiary)
  • Laurus Generics Inc., USA (Step-down Subsidiary)
  • Laurus Generics GmbH, Germany (Step-down Subsidiary)
  • Laurus Generics SA (Pty) Limited, South Africa (Wholly Owned Subsidiary)
  • Laurus Specialty Chemicals Private Limited, India (Wholly Owned Subsidiary)
  • ImmunoAdoptive Cell Therapy Private Limited, India (Associate, 34.89% holding)
  • Ethan Energy India Private Limited, India (Associate, 26.00% holding)
  • KRKA Pharma Private Limited, India (Joint Venture, 49.00% holding)

Capital Expenditure:

Significant increase in Capital Work-in-Progress:

  • Consolidated: ₹1,282.44 Cr (vs. ₹773.28 Cr as of Mar 31, 2026)
  • Standalone: ₹974.81 Cr (vs. ₹569.42 Cr as of Mar 31, 2026)

Cash Flow:

  • Consolidated operating cash flow for H1 FY27 was ₹804.96 Cr, while investing cash flow was an outflow of ₹863.12 Cr (primarily due to purchase of PPE/CWIP).
  • Standalone operating cash flow for H1 FY27 was ₹660.21 Cr, while investing cash flow was an outflow of ₹671.28 Cr.